RICHMOND, Va. / Dec 02, 2025 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) announced today that members of its management team are scheduled to participate in two upcoming investor conferences.
Citi 2025 Global Healthcare Conference
On Tuesday, December 2, 2025, Ed Pesicka, the Company’s President and Chief Executive Officer, and Will Parrish, the Company’s Vice President of Strategy, Corporate Development, & Investor Relations, are scheduled to participate in a fireside chat at 2:30 P.M. ET and host one-on-one investor meetings at the conference in Miami, Florida.
Please visit the “Events & Presentations” section of the “Investor Relations” page on the Owens & Minor website available at https://investors.owens-minor.com at least 10 minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.
Bank of America Leveraged Finance Conference
On Tuesday, December 2, 2025, Jon Leon, the Company’s Executive Vice President and Chief Financial Officer, and Alex Miller, the Company’s Vice President of Tax & Treasury, are scheduled to host one-on-one investor meetings at the conference in Boca Raton, Florida.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
| Last Trade: | US$2.68 |
| Daily Change: | 0.01 0.37 |
| Daily Volume: | 669,227 |
| Market Cap: | US$207.300M |
October 30, 2025 October 07, 2025 September 15, 2025 August 11, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load